ACADIA Pharmaceuticals Inc.

Good day, ladies and gentlemen, and welcome to Acadia Pharmaceutical's third quarter 2022 financial results conference call. My name is Gigi, and I'll be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at Acadia. Please proceed.

Thank you, Gigi.

Good afternoon and thank you for joining us on today's call to discuss Acadia's third quarter 2022 financial results. Joining me on the call today from Acadia are Steve Davis, our chief executive officer, who will provide an overview of our third quarter performance and a review of our business. Brendan Ian, our chief operating officer, head of commercial, will provide updates on our commercial performance. And Kathy Bishop, our chief scientific officer and head of rare disease, will provide an overview of terpenetide. Dr. Serge Sankovich, our president, will then discuss our pipeline progress And Mark Schneier, our Chief Financial Officer, will discuss our financial results and guidance before turning it back to Steve for final remarks and opening the call up for your questions. I would also like to point out that we're using supplement slides, which are available on the events and presentation section of our website. Before we proceed, I would first like to remind you that during our call today, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, or future results are based on current information, assumptions, and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. We're cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date. I'll now turn the call over to Steve.